


**Claims:**

1. A compound of formula (1):



5

wherein:

Y is a linking group -C(O)- or -S(O)₂-;

10 n is zero or the integer 1;

m is the integer 1, 2, 3 or 4;

p is the integer 1, 2, 3 or 4;

R⁴ is an -OH, -(Alk²)OH (where Alk² is a straight or branched C<sub>1-4</sub> alkylene chain), -OR¹ (where R¹ is a straight or branched C<sub>1-6</sub> alkyl group), -(Alk²)OR¹,

15 -NR²R³ (where R² and R³ may be the same or different and is each independently a hydrogen atom or a straight or branched C<sub>1-6</sub> alkyl group), -(Alk²)NR²R³ or straight or branched C<sub>1-6</sub> alkyl group;

Alk¹ is a straight or branched C<sub>1-4</sub> alkylene chain;

Cy¹ is an optionally substituted cycloaliphatic, aromatic or heteroaromatic

20 group; and

Ar is an optionally substituted aromatic or heteroaromatic group;

and the salts, solvates, hydrates and N-oxides thereof.

2. A compound as claimed in claim 1 wherein R⁴ is -OH, -(Alk²)OH, 25 -(Alk²)OR¹, -NR²R³ or -(Alk²)NR²R³, in which Alk², R¹, R² and R³ are as defined in claim 1.

3. A compound as claimed in claim 1 or claim 2 wherein Alk<sup>2</sup> is -CH<sub>2</sub>- or -C(CH<sub>3</sub>)<sub>2</sub>-.

5 4. A compound as claimed in any one of the preceding claims wherein R<sup>1</sup> is methyl.

5. A compound as claimed in any one of the preceding claims wherein R<sup>2</sup> is hydrogen or methyl.

10

6. A compound as claimed in any one of the preceding claims wherein R<sup>3</sup> is hydrogen or methyl.

15

7. A compound as claimed in any one of the preceding claims wherein Cy<sup>1</sup> is phenyl, fluorophenyl, chlorophenyl, methylphenyl or cyclopropyl.

8. A compound as claimed in any one of the preceding claims wherein Ar is phenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, chlorophenyl, cyanophenyl or methylphenyl.

20

9. A compound as claimed in claim 1 as herein specifically disclosed in any one of the Examples.

25

10. A pharmaceutical composition comprising a compound of formula (1) as defined in claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or N-oxide thereof, in association with a pharmaceutically acceptable carrier.

30

11. The use of a compound of formula (1) as defined in claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or N-oxide thereof, for the manufacture of a medicament for the treatment and/or prevention of a disorder for which an inhibitor of p38 MAP kinase is indicated.

12. A method for the treatment and/or prevention of a disorder for which an inhibitor of p38 MAP kinase is indicated, which comprises administering to a patient in need of such treatment a compound of formula (1) as defined in  
5 claim 1, or a pharmaceutically acceptable salt, solvate, hydrate or *N*-oxide thereof.